Mod­er­na sticks to long-term strat­e­gy in first-quar­ter up­date, ends pact with Metageno­mi

Mod­er­na’s shift to a more “re­strained” pos­ture was on full dis­play Thurs­day morn­ing dur­ing its first-quar­ter earn­ings up­date.

CEO Stéphane Ban­cel and his team stayed away from mak­ing bold promis­es like they did in the past, as the com­pa­ny con­tin­ued to em­pha­size a re­turn to growth by 2026. De­spite be­ing pelt­ed by an­a­lysts’ ques­tions about the fu­ture of its vac­cines — RSV, with a PDU­FA date of May 12, was a par­tic­u­lar fo­cus — ex­ecs shared few de­tails be­yond what they’ve dis­closed at oth­er events this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER